indatuximab ravtansine (BT-062) - ImmunoGen, ADMA Biologics
Biotest: Q3 FY 2015 Results (Biotest) - Nov 14, 2015 - "BT-062 Phase I/IIa Study No. 983 in Multiple Myeloma"; "Results of BT-062 with Pomalidomide / Dexamethasone"; "A total of 17 patients were enrolled"; "13 patients are on treatment without progressive disease" 
P1/2 data Multiple Myeloma • Oncology
http://www.biotest.com/de/en/investor_relations/news_and_publications/publications/presentations_and_analyst_call.cfm
 
Nov 14, 2015
 
 
bbe8c241-a123-4c64-ad21-20ac760fcba2.jpg